{"id":"NCT01519713","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Study of a Single Dose of Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284) in Japanese Subjects","officialTitle":"Immunogenicity and Safety of a Single Dose of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284) in Japanese Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-01","primaryCompletion":"2012-09","completion":"2012-12","firstPosted":"2012-01-27","resultsPosted":"2013-05-28","lastUpdate":"2013-05-28"},"enrollment":200,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Meningitis","Meningococcal Meningitis","Meningococcal Infections"],"interventions":[{"type":"BIOLOGICAL","name":"Meningococcal polysaccharide diphtheria toxoid conjugate","otherNames":["Menactra®, SP284"]}],"arms":[{"label":"Adults Study Group","type":"EXPERIMENTAL"},{"label":"Adolescents Study Group","type":"EXPERIMENTAL"},{"label":"Children Study Group","type":"EXPERIMENTAL"}],"summary":"This study is designed to assess the safety and immunogenicity of a single dose of Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284) to support registration of the product in Japan.\n\nPrimary Objective:\n\n* To describe the seroprotection rate \\[% of subjects with serum bactericidal assay using baby rabbit complement (SBA-BR) ≥1:128\\] to meningococcal antigens (serogroups A, C, Y and W-135) following vaccination with SP284 vaccine in subjects 2 through 55 years of age\n\nSecondary Objectives:\n\n* To describe the safety following receipt of SP284 vaccine in subjects 2 through 55 years of age\n* To describe the immune responses to meningococcal antigens (serogroups A, C, Y and W-135) following vaccination with SP284 vaccine in subjects 2 through 55 years of age.","primaryOutcome":{"measure":"Number of Participants With Serum Bovine Albumin Baby Rabbit (SBA-BR) Titers of >=1:128 Following Vaccination With One Dose of Menactra® Vaccine","timeFrame":"28 Days post-vaccination","effectByArm":[{"arm":"Adults Menactra® Vaccine Group","deltaMin":177,"sd":null},{"arm":"Adolescents Menactra® Vaccine Group","deltaMin":2,"sd":null},{"arm":"Children Menactra® Vaccine Group","deltaMin":4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":20},"locations":{"siteCount":3,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":["http://www.sanofipasteur.com"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":194},"commonTop":["Injection site pain","Myalgia","Malaise","Nasopharyngitis","Injection site erythema"]}}